Remora Biotech
Richard Groenendijk is a seasoned finance professional with extensive experience in the biotech and capital markets sectors. Currently serving as Managing Partner and CFO at Remora Biotech since May 2018, Richard Groenendijk plays a pivotal role in supporting growth for the venture builder specializing in immunotherapy. Additionally, Richard Groenendijk is a board member at MKB Biopharma. Prior experience includes a tenure at CONTINENTAL CAPITAL MARKETS S.A. as Senior Advisor for Russia and Manager of Emerging Markets, along with a position as Head of CIS/Balkans and Senior Partner at Kepler Cheuvreux. Richard Groenendijk began a career at Rabobank where responsibilities spanned global foreign exchange sales, trading, and client management. Richard Groenendijk holds a degree from Amsterdam University of Applied Sciences.
This person is not in any teams
Remora Biotech
Immunotherapy has an immense and growing impact on medicine and society : vaccines against pandemics, monoclonal antibodies – the most successful class of drugs, breakthrough cures of cancer and autoimmune diseases, and new hopes to fight degenerative diseases. As immunologists and serial entrepreneurs, we contributed, at our small individual scale, to this biopharmaceutical revolution driven by immunology. We now join forces at Remora Biotech to leverage our entrepreneurial experience and, thanks to our supporting investors, to scale-up our ability to nurture and develop innovative life-changing immunotherapies. With our growing team and network of academic partners, business-oriented scientists, patent experts, drug developers and finance professionals, we create, finance, and manage a portfolio of daughter companies from discovery to clinical proof-of-concept. We aim at maximizing their odds of success and their strategic value for pharma partners while keeping capital efficient. Investors keen to gain exposure to this high-growth and high-impact sector, under the leadership of seasoned entrepreneurs, may become a shareholder of Remora Biotech and co-invest in our daughter companies.